

Product identifier



SAFETY DATA SHEET

100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Desident Name	Anti-Liuman III A DD. Clans I 242, ADC	
Product Name	Anti-Human HLA-DR, Clone L243, APC	
Other means of identification		
Catalog Number	100-0335 100-0336	
Document Number	1000007882	
Synonym	None	
Recommended use of the chemical and restrictions on use		
Recommended Use	Laboratory reagent	
Details of the supplier of the safety	data sheet	
Manufacturer/Supplier STEMCELL Technologies Canada Inc Suite 500 - 1618 Station Street Vancouver, British Columbia V6A 1B6		
Emergency telephone number		
Emergency Telephone	1-800-667-0322	
	2. HAZARDS IDENTIFICATION	
<u>Classification</u>		
This chemical is not considered hazard	dous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)	

Hazards not otherwise classified (HNOC)

Label elements





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

The product contains no substances which at their given concentration, are considered to be hazardous to health.

Appearance Clear

Physical state Liquid

Odor No data available

Other Information

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance

Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of first aid measures

Inhalation	Remove to fresh air.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Wash skin with soap and water.
Ingestion	Clean mouth with water and drink afterwards plenty of water.





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

Most important symptoms and effects, both acute and delayed		
Symptoms	No information available.	
Indication of any immediate medical attention and special treatment needed		
Note to physicians	Treat symptomatically.	
	5. FIRE-FIGHTING MEASURES	
Suitable Extinguishing Media	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.	
Unsuitable extinguishing media	CAUTION: Use of water spray when fighting fire may be inefficient.	
Specific hazards arising from the chemical	No information available.	
Explosion data Sensitivity to Mechanical Impact None. Sensitivity to Static Discharge None.		
Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.	

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions	Ensure adequate ventilation.	
Environmental precautions		
Environmental precautions	See Section 12 for additional Ecological Information.	
Methods and material for containment and cleaning up		
Methods for containment	Prevent further leakage or spillage if safe to do so.	
Methods for cleaning up	Pick up and transfer to properly labeled containers.	
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.	





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Store in accordance with information listed on the Product Information Sheet (PIS).

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Limits	This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.	
Other Information	Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir., 1992).	
Appropriate engineering controls		
Engineering controls	Showers Eyewash stations Ventilation systems.	
Individual protection measures, such as personal protective equipment		
Eye/face protection	No special protective equipment required.	
Skin and body protection	No special protective equipment required.	
Respiratory protection	No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.	
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.	

9. PHYSICAL AND CHEMICAL PROPERTIES





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No data available
Odor threshold	No data available

Property pН Melting point / freezing point Boiling point / boiling range Flash point **Evaporation rate** Flammability (solid, gas) Flammability Limit in Air Upper flammability limit: Lower flammability limit: Vapor pressure Vapor density **Relative density** Water solubility Solubility in other solvents **Partition coefficient** Autoignition temperature **Decomposition temperature Kinematic viscosity Dynamic viscosity Explosive properties Oxidizing properties**

Other Information Softening point Molecular weight Molecular formula VOC Content (%) Liquid Density **Bulk density**

Values No data available No data available No data available No data available No data available

No data available

No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available No information available

No information available No information available No information available No information available No information available No information available

Remarks • Method

None known None known None known None known None known None known None known

None known None known None known None known None known None known None known None known None known None known

10. STABILITY AND REACTIVITY

Reactivity	No information available.
Chemical stability	Stable under normal conditions.
Possibility of hazardous reactions	None under normal processing.
Conditions to avoid	None known based on information supplied.





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

Incompatible materials None known based on information supplied.

Hazardous decomposition products None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information	
Inhalation	Specific test data for the substance or mixture is not available.
Eye contact	Specific test data for the substance or mixture is not available.
Skin contact	Specific test data for the substance or mixture is not available.
Ingestion	Specific test data for the substance or mixture is not available.
Symptoms related to the physical,	chemical and toxicological characteristics
Symptoms	No information available.
Numerical measures of toxicity	
Acute toxicity	
100 % of the mixture consists of 100 % of the mixture consists of 100 % of the mixture consists of	0 % of the mixture consists of ingredient(s) of unknown toxicity gredient(s) of unknown acute oral toxicity ingredient(s) of unknown acute dermal toxicity ingredient(s) of unknown acute inhalation toxicity (gas) ingredient(s) of unknown acute inhalation toxicity (vapor) gredient(s) of unknown acute inhalation toxicity (dust/mist)
Delayed and immediate effects as	well as chronic effects from short and long-term exposure
Skin corrosion/irritation	No information available.
Product Information	
Serious eye damage/eye irritation	No information available.
Product Information	
Respiratory or skin sensitization	No information available.

Product Information





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

Germ cell mutagenicity	No information available.
Product Information	
Carcinogenicity	No information available.
Reproductive toxicity	No information available.
	Product Information
STOT - single exposure	No information available. Product Information
STOT - repeated exposure	No information available. Product Information
Aspiration hazard	No information available.

12. ECOLOGICAL INFORMATION

Ecotoxicity Product Information	
Persistence and degradability	No information available.
Bioaccumulation	There is no data for this product.
Other adverse effects	No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods	
Waste from residues/unused products	Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.
Contaminated packaging	Do not reuse empty containers.
US EPA Waste Number	P105





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

14. TRANSPORT INFORMATION

DOT	Not regulated
TDG	Not regulated
<u>MEX</u>	Not regulated
ICAO (air)	Not regulated
IATA	Not regulated
IMDG	Not regulated
RID	Not regulated
ADR	Not regulated
ADN	Not regulated

15. REGULATORY INFORMATION

International Inventories	
TSCA	Complies
DSL/NDSL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

US Federal Regulations

<u>SARA 313</u>

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

SARA 311/312 Hazard CategoriesAcute health hazardNoChronic Health HazardNoFire hazardNoSudden release of pressure hazardNoReactive HazardNo

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

This product does not contain any substances regulated under applicable state right-to-know regulations

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water	-	-	Х
7732-18-5			
Sodium Azide	Х	X	Х
26628-22-8			

U.S. EPA Label Information

16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By,	Quality Control. STEMCELL Technologies Canada Inc.
Revision Date	28-Mar-2023
Revision Note <u>Disclaimer</u>	No information available.





100-0335 100-0336 - Anti-Human HLA-DR, Clone L243, APC

Revision Date 28-Mar-2023 Revision Number 1.1

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

End of Safety Data Sheet